Esmo 2023: agenus' botensilimab/balstilimab combination delivers durable responses across multiple sarcoma subtypes

Lexington, mass.--(business wire)--agenus inc. (nasdaq:agen), a leader in developing novel immunological agents to treat various cancers, today announced expanded data from the company's phase 1b study of botensilimab (bot, multifunctional immune activator) in combination with balstilimab (bal, anti-pd-1) in patients with advanced sarcomas. the results were presented in an oral presentation at the european society for medical oncology (esmo) congress 2023. relapsed/refractory sarcoma represents.
AGEN Ratings Summary
AGEN Quant Ranking